Neurocrine Biosciences has successfully diversified beyond Ingrezza, with Crenessity's rapid adoption validating its multi-franchise commercial strategy. NBIX's late-stage neuropsychiatry pipeline, ...
“Our commercial portfolio of first-in-class medicines, INGREZZA, CRENESSITY and VYKAT XR delivered another record quarter with net product sales exceeding $950 million,” said (President, CEO & ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Hosted on MSN
Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close
CEO Kyle Gano said Q1 marked a commercial milestone: "For the first time in Neurocrine's history, quarterly net product sales exceeded $800 million, representing 44% year-over-year growth," adding the ...
Detailed price information for Neurocrine Bioscienc (NBIX-Q) from The Globe and Mail including charting and trades.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
While 2017 saw the entrance of the first two drugs for tardive dyskinesia, the percentage of TD patients who are actually diagnosed remains in the single digits. Neurocrine is looking to change that ...
INGREZZA showed higher rates of long-term treatment continuation and lower switching between medications compared to AUSTEDO XR (deutetrabenazine) in a real-world claims analysis among adults with ...
SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results